# EDGAR Filing Document

**Accession Number:** 0001641281
**File Stem:** 0001193125-26-104164
**Filing Date:** 2026-3
**Character Count:** 23175
**Document Hash:** a2c3e2d0eea6860c9d5b62ad499ed95d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-104164.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001193125-26-104164

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**EFFECTIVENESS DATE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bolt Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001641281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472804636
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294245
- **FILM NUMBER:** 26747897

**BUSINESS ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-665-9295

**MAIL ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bolt Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150504

**As filed with the U.S. Securities and Exchange Commission on March 12, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

**BOLT BIOTHERAPEUTICS, INC.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **47-2804636** |
| **(State or other jurisdiction of**<br>**Incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**900 Chesapeake Drive** 

**Redwood City, California 94063** 

**(650) 665-9295** 

**(Address of principal executive offices) (Zip code)** 

**Bolt Biotherapeutics, Inc. 2021 Equity Incentive Plan** 

**Bolt Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**William P. Quinn** 

**Chief Executive Officer** 

**Bolt Biotherapeutics, Inc.** 

**900 Chesapeake Drive** 

**Redwood City, California 94063** 

**(650) 665-9295** 

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)**

***Copy to:*** 

**John T. McKenna** 

**Cooley LLP** 

**3175 Hanover Street** 

**Palo Alto, CA 94304**

**(650) 843-5000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

------

**EXPLANATORY NOTE** 

Bolt Biotherapeutics, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 for the purpose of registering an additional (a) 96,028 shares of its common stock, par value $0.00001 per share (the "***Common Stock***"), issuable to eligible persons under the 2021 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant's registration statement on Form S-8s filed on [<u>February 5, 2021 (File No. 333-252815)</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521030982/d94530ds8.htm), [<u>March 30, 2022 (File No. 333-263987)</u>](https://www.sec.gov/Archives/edgar/data/1641281/000156459022012641/bolt-s8.htm), [<u>March 29, 2023 (File No. 333-270938),</u>](https://www.sec.gov/Archives/edgar/data/1641281/000095017023010624/0000950170-23-010624-index.htm)[<u>March 21, 2024 (File No. 333-278141)</u>](https://www.sec.gov/Archives/edgar/data/1641281/000095017024034711/2024_s-8_evergreen.htm), and [<u>March 24, 2025 (File No. 333-286056)</u>](https://www.sec.gov/Archives/edgar/data/1641281/000095017025043900/2025_s-8_evergreen.htm)(the "***Prior Form S-8s***"), and (b) 19,205 shares of Common Stock issuable to eligible persons under the 2021 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the Prior Form S-8s.

**PART II** 

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**  |

---

Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated by reference herein.

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

(a) The Registrant's [<u>Annual Report on Form 10-K</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001641281/000119312526104121/bolt-20251231.htm)for the fiscal year ended December 31, 2025 filed on March 12, 2026, which contains audited financial statements for the Registrant's latest fiscal year.

(b) The description of the Common Stock which is contained in a registration statement on [<u>Form 8-A</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521025784/d38933d8a12b.htm) filed on February 2, 2021 (File No. 001-39988) under the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), including any amendment or report filed for the purpose of updating such description.

(c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS**  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |  |
| **Exhibit<br>Number** | **Description** | **Schedule<br>Form** | **File Number** | **Exhibit** | **Filing Date** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521034375/d68629dex31.htm) | 8-K | 001-39988 | 3.1 | 2/9/2021 |
| 4.2 | [<u>Certificate of Amendment to Amended and Restated Certificate of Incorporation.</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001641281/000095017025083180/bolt-20250606.htm) | 8-K | &nbsp;&nbsp;&nbsp;&nbsp;001-39988 | 3.1 | 6/6/2025 |
| 4.3 | [<u>Amended and Restated Bylaws of the Registrant, as currently in effect</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001641281/000095017025054871/bolt-20250415.htm)<u>.</u> | 8-K | 001-39988 | 3.1 | &nbsp;&nbsp;&nbsp;&nbsp;4/16/2025 |
| 4.4 | [<u>Form of common stock certificate of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521010049/d58029dex41.htm) | S-1 | 333-252136 | 4.1 | 1/15/2021 |
| 5.1\* | [<u>Opinion of Cooley LLP.</u>](bolt-ex5_1.htm) |  |  |  |  |
| 23.1\* | [<u>Consent of Independent Registered Public Accounting Firm.</u>](bolt-ex23_1.htm) |  |  |  |  |
| 23.2\* | [<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](bolt-ex5_1.htm) |  |  |  |  |
| 24.1\* | [<u>Power of Attorney (see signature page hereto).</u>](#sig) |  |  |  |  |
| 99.1 | [<u>2021 Equity Incentive Plan.</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521023574/d58029dex104.htm) | S-1/A | 333-252136 | 10.4 | 2/1/2021 |
| 99.2 | [<u>2021 Employee Stock Purchase Plan.</u>](https://www.sec.gov/Archives/edgar/data/1641281/000119312521023574/d58029dex107.htm) | S-1/A | 333-252136 | 10.7 | 2/1/2021 |
| 107\* | [<u>Filing Fee Table.</u>](bolt_exfilingfees.htm) |  |  |  |  |

---

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on March 12, 2026.

---

| | |
|:---|:---|
| **BOLT BIOTHERAPEUTICS, INC.** | **BOLT BIOTHERAPEUTICS, INC.** |
| By: | /s/ William P. Quinn |
|  | William P. Quinn |
|  | President, Chief Executive Officer and Chief Financial Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William P. Quinn and Sarah Nemec, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ William P. Quinn | President, Chief Executive Officer and Chief Financial Officer | March 12, 2026 |
| William P. Quinn | *(Principal Executive and Financial Officer)* |  |
| /s/ Sarah Nemec | Senior Vice President, Finance | March 12, 2026 |
| Sarah Nemec | *(Principal Accounting Officer)* |  |
| /s/ Brian O'Callaghan | Chairman | March 12, 2026 |
| Brian O'Callaghan |  |  |
| /s/ Laura Berner | Director | March 12, 2026 |
| Laura Berner |  |  |
| /s/ Jakob Dupont, M.D. | Director | March 12, 2026 |
| Jakob Dupont, M.D. |  |  |
| /s/ Kathleen LaPorte | Director | March 12, 2026 |
| Kathleen LaPorte |  |  |
| /s/ Nicole Onetto, M.D. | Director | March 12, 2026 |
| Nicole Onetto, M.D. |  |  |

---

------

## Exhibit 5.1

![img38739919_0.gif](img38739919_0.gif)

John T. McKenna+1 650 843 5059jmckenna@cooley.com

March 12, 2026

Bolt Biotherapeutics, Inc.

900 Chesapeake Drive

Redwood City, CA 94063

Ladies and Gentlemen:

We have acted as counsel to Bolt Biotherapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission*"**) covering the offering of up to an aggregate of 115,233 shares (the "***Shares***") of the Company's Common Stock, par value $0.00001 per share ("***Common Stock***"), consisting of (a) 19,205 shares of Common Stock issuable pursuant to the Company's 2021 Employee Stock Purchase Plan (the "***2021 ESPP***") and (b) 96,028 shares of Common Stock issuable pursuant to the Company's 2021 Equity Incentive Plan (together with the 2021 ESPP, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plans, (c) the Company's certificate of incorporation and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

------

![img38739919_1.gif](img38739919_1.gif)

Bolt Biotherapeutics, Inc.March 12, 2026 Page 2

Sincerely,

**Cooley LLP**

By: <u>/s/ John T. McKenna</u> 

John T. McKenna

------

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Bolt Biotherapeutics, Inc. of our report dated March 12, 2026 relating to the financial statements, which appears in Bolt Biotherapeutic, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP<br>San Jose, California<br>March 12, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107** 

**Calculation of** Filing Fee **Table** 

<u>Form</u> S-8

(Form Type)

Bolt Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br>Type** | **Security Class Title** | **Fee<br>Calculation<br>Rule** | **Amount<br>Registered**<sup>(1)</sup> | **Proposed<br>Maximum**<br>**Offering<br>Price Per<br>Unit** | **Maximum<br>Aggregate**<br>**Offering<br>Price** | **Fee Rate** | **Amount of<br>Registration<br>Fee** |
| 1 | Equity | Common Stock, par value $0.00001 per share, Bolt Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan | Other | 19205 | $3.56 | $68370 | $0.00013810 | $9.45 |
| 2 | Equity | Common Stock, par value $0.00001 per share, Bolt Biotherapeutics, Inc. 2021 Equity Incentive Plan | Other | 96028 | $4.19 | $402357 | $0.00013810 | $55.57 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | **$470727** |  | **$65.02** |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | **$65.02** |

---

**Offering Note**

**(1)** **A.** Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "***Securities Act***"), this Registration Statement shall also cover any additional shares of common stock, $0.00001 par value per share ("***Common Stock***") of Bolt Biotherapeutics, Inc. (the "***Registrant***") that become issuable under the Registrant's 2021 Employee Stock Purchase Plan (the "***2021 ESPP***") and the Registrant's 2021 Equity Incentive Plan (the "***2021 Plan***") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's Common Stock, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** The proposed maximum offering price per unit is estimated in accordance with Rules 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $3.56 per share of Common Stock, which represents the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Capital Market on March 9, 2026, multiplied by 85%, which is the percentage of the price per share applicable to shares issued under the 2021 ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** The amount registered represents 19,205 additional shares of the Registrant's Common Stock that were added to the shares authorized for issuance under the 2021 ESPP pursuant to an annual "evergreen" increase provision contained in the 2021 ESPP. Pursuant to such provision, the number of shares reserved for issuance under the 2021 ESPP will increase on January 1 of each calendar year that commences after the 2021 ESPP became effective and continuing through and including January 1, 2031, by the lesser of (a) 1% of the total number of shares of the Registrant's Common Stock outstanding on December 31 of the preceding calendar year, (b) 42,000 shares, and (c) a number of shares determined by the Registrant's board of directors.

**(2)** **A.** See Note 1A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** The proposed maximum offering price per unit is estimated in accordance with Rules 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $4.19 per share of Common Stock, which represents the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Capital Market on March 9, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C.** The amount registered represents 96,028 additional shares of the Registrant's Common Stock that were added to the shares authorized for issuance under the 2021 Plan pursuant to an annual "evergreen" increase

------

provision contained in the 2021 Plan. Pursuant to such provision, the number of shares reserved for issuance under the 2021 Plan will increase on the first day of January of each calendar year that commences after the 2021 Plan became effective and continuing through and including January 1, 2031, in an amount equal to 5% of the total number of shares of the Registrant's Common Stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Registrant's board of directors.

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** | &nbsp;&nbsp;**Table 2: Fee Offset Claims and Sources**<br>**☑ Not Applicable** |
|  | &nbsp;&nbsp;**Registrant<br>or Filer<br>Name** | &nbsp;&nbsp;**Form or<br>Filing<br>Type** | &nbsp;&nbsp;**File<br>Number** | &nbsp;&nbsp;**Initial<br>Filing<br>Date** | &nbsp;&nbsp;**Filing<br>Date** | &nbsp;&nbsp;**Fee<br>Offset<br>Claimed** | &nbsp;&nbsp;**Security<br>Type<br>Associated<br>with Fee<br>Offset<br>Claimed** | &nbsp;&nbsp;**Security<br>Title<br>Associated<br>with Fee<br>Offset<br>Claimed** | &nbsp;&nbsp;**Unsold<br>Securities<br>Associated<br>with Fee<br>Offset<br>Claimed** | &nbsp;&nbsp;**Unsold<br>Aggregate<br>Offering<br>Amount<br>Associated with<br>Fee Offset<br>Claimed** | &nbsp;&nbsp;**Fee<br>Paid<br>with<br>Fee<br>Offset<br>Source** |
| &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** | &nbsp;&nbsp;**Rule 457(p)** |
| &nbsp;&nbsp;Fee Offset Claims | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;Fee Offset Sources | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A |

---

------